Structure

InChI Key IQPNAANSBPBGFQ-UHFFFAOYSA-N
Smiles O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12
InChI
InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H10O6
Molecular Weight 286.24
AlogP 2.28
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 1.0
Polar Surface Area 111.13
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 21.0
Assay Description Organism Bioactivity Reference
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 0 uM concentration Rattus norvegicus 0.0 %
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 10 uM concentration Rattus norvegicus 89.4 %
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 3 uM concentration Rattus norvegicus 41.6 %
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 30 uM concentration Rattus norvegicus 99.2 %
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 0 uM concentration Rattus norvegicus 0.0 %
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 10 uM concentration Rattus norvegicus 89.0 %
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 3 uM concentration Rattus norvegicus 25.0 %
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 30 uM concentration Rattus norvegicus 101.3 %
Inhibition of glycogen synthase kinase 3 None 800.0 nM
Inhibition of FabG in presence of NADPH Plasmodium falciparum 800.0 nM
Peroxynitrite scavenging activity assessed as inhibition of DHR oxidation None 300.0 nM
Peroxynitrite scavenging activity assessed as inhibition of DHR oxidation in presence of NaHCo3 None 640.0 nM
Inhibition of COX2 in I1-10-stimulated bone marrow derived mast cells None 80.0 %
Inhibition of COX2 at 100 uM by scintillation proximity assay None 30.0 %
Inhibition of COX2 None 100.0 ug.mL-1
Inhibition of COX2 in LPS-stimulated bone marrow derived mast cells None 2.5 ug.mL-1
Inhibition of bovine thymus p56LCK-catalyzed phosphorylation of angiotensin 1 by SDS-PAGE Bos taurus 10.0 ug.mL-1
Inhibition of bovine thymus p56-LCK protein tyrosine kinase activity Bos taurus 4.0 ug.mL-1
Inhibition of Saccharomyces cerevisiae fatty acid synthase Saccharomyces cerevisiae 9.0 ug.mL-1
Antifungal activity against Candida albicans ATCC 90028 Candida albicans 50.0 ug.mL-1
Antifungal activity against Cryptococcus neoformans ATCC 90113 Cryptococcus neoformans 50.0 ug.mL-1
Inhibition of p56 lck None 10.0 ug.mL-1
Cytotoxicity against human HL60 cells after 3 days by MTT assay Homo sapiens 10.0 ug.mL-1
Cytotoxicity against human SW1573 cells after 3 days by MTT assay Homo sapiens 10.0 ug.mL-1
Cytotoxicity against human CEM cells after 3 days by MTT assay Homo sapiens 10.0 ug.mL-1
Antioxidant activity assessed as DPPH free radical scavenging activity None 7.2 ug.mL-1
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release Homo sapiens 12.1 ug.mL-1
Inhibition of xanthine oxidase assessed as decrease in uric acid production by spectrophotometry None 550.0 nM
Inhibition of COX2 at 2.5 ug/mL None 80.0 %
Inhibition of COX1 at 2.5 ug/mL None 75.0 %
Inhibition of human salivary alpha-amylase Homo sapiens 88.8 %
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 30 uM after 72 hrs Mus musculus 76.7 %
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 10 uM after 72 hrs Mus musculus 38.1 %
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 3 uM after 72 hrs Mus musculus 13.5 %
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 1 uM after 72 hrs Mus musculus 6.2 %
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 1 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Mus musculus -4.8 %
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 3 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Mus musculus -4.9 %
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 10 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Mus musculus 4.0 %
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 30 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay Mus musculus 23.4 %
Inhibition of mushroom tyrosinase at 1 uM Agaricus bisporus 6.4 %
Inhibition of mushroom tyrosinase at 3 uM Agaricus bisporus 7.1 %
Inhibition of mushroom tyrosinase at 10 uM Agaricus bisporus 9.2 %
Inhibition of mushroom tyrosinase at 30 uM Agaricus bisporus 12.1 %
Inhibition of mushroom tyrosinase at 100 uM Agaricus bisporus 17.6 %
Inhibition of rat liver DNA topoisomerase 1 preincubated before addition of DNA Rattus norvegicus 660.0 nM
Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay Influenza A virus (A/Puerto Rico/8/1934(H1N1)) 9.65 ug.mL-1
Inhibition of human CYP1B1 by EROD assay Homo sapiens 79.0 nM
Inhibition of NOX4 expressed in HEK293 FS cells at 10 uM assessed as H2O2 production by H2O2/Tyr/LPO assay None 106.0 %
Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay None 850.0 nM
Cytotoxicity against human free style HEK293 cells after 72 hrs Homo sapiens -4.47 %
Inhibition of NOX4 expressed in HEK293 FS cells at 10 uM assessed as H2O2 production by H2O2/Tyr/LPO assay substituted with 3 uM H2O2 None 110.36 %
Cytotoxicity against human HepG2 cells by MTT assay Homo sapiens 7.36 ug.mL-1
Cytotoxicity against human Hep3B cells by MTT assay Homo sapiens 8.03 ug.mL-1
Cytotoxicity against human Ca9-22 cells by MTT assay Homo sapiens 8.55 ug.mL-1
Cytotoxicity against human A549 cells by MTT assay Homo sapiens 10.23 ug.mL-1
Cytotoxicity against human MCF7 cells by MTT assay Homo sapiens 9.5 ug.mL-1
Cytotoxicity against human MDA-MB-231 cells by MTT assay Homo sapiens 9.65 ug.mL-1
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Homo sapiens 2.56 ug.mL-1
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Homo sapiens 50.0 ug.mL-1
Inhibition of CYP1A1 EROD activity assessed as inhibition of deethylation of 7-ethoxyresorufin to resorufin None 890.0 nM
Inhibition of CYP1B1 EROD activity assessed as inhibition of deethylation of 7-ethoxyresorufin to resorufin None 56.0 nM
Inhibition of Xanthomonas oryzae pv. oryzae KS-1-21 uridyltransferase domain of GlmU activity by ion-pair reverse-phase HPLC analysis Xanthomonas oryzae pv. oryzae 810.0 nM
Competitive inhibition of Xanthomonas oryzae pv. Oryzae KS-1-21 GlmU using 0.25 to 0.05 mM GlcNAc-1-p and 500 uM UTP by Lineweaver-Burk plot analysis Xanthomonas oryzae pv. oryzae 440.0 nM
Uncompetitive inhibition of Xanthomonas oryzae pv. Oryzae KS-1-21 GlmU using varying concentration of UTP and 500 uM GlcNAc-1-p by Lineweaver-Burk plot analysis Xanthomonas oryzae pv. oryzae 990.0 nM
Inhibition of human recombinant MMP12 catalytic domain incubated for 20 mins by fluorimetric assay Homo sapiens 980.0 nM
Inhibition of human recombinant MMP2 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay Homo sapiens 30.0 %
Inhibition of human recombinant MMP3 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay Homo sapiens 30.0 %
Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay Homo sapiens 30.0 %
Inhibition of human recombinant MMP12 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay Homo sapiens 30.0 %
Inhibition of human recombinant MMP13 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay Homo sapiens 30.0 %
Antioxidant activity assessed as DPPH free radical scavenging activity None 44.18 ug.mL-1
Antioxidant activity assessed as superoxide radical scavenging activity None 31.01 ug.mL-1
Antioxidant activity of the compound assessed as inhibition of lipid peroxidation None 134.1 ug.mL-1
Antioxidant activity in erythrocytes assessed as inhibition of hemolysis None 122.0 ug.mL-1
Cytotoxicity against TRAIL-resistant human AGS cells assessed as inhibition of cell viability at 17.5 uM after 24 hrs by fluorescence assay in presence of 100 ng/ml TRAIL relative to in absence of TRAIL Homo sapiens 48.0 %
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method Electrophorus electricus 13.58 %
Inhibition of horse BChE at 2 mg/ml by Ellman's method Equus caballus 0.42 %
Inhibition of alpha-glucosidase (unknown origin) using para-nitrophenyl-alpha-D-glucopyranoside as substrate incubated at 50 to 300 ug/ml for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis Homo sapiens 99.89 %
Antioxidant activity assessed as as DPPH radical scavenging activity after 30 min by spectrophotometry None 0.99 ug.mL-1
Inhibition of alpha-glucosidase (unknown origin) using para-nitrophenyl-alpha-D-glucopyranoside as substrate incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis Homo sapiens 5.96 ug.mL-1
Antifungal activity against Verticillium dahliae assessed as inhibition of mycelial radial growth measured after 350 hr Verticillium dahliae 7.0 ug.mL-1
Antiamoebic activity against Entamoeba histolytica Entamoeba histolytica 17.8 ug.mL-1
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 16 g/l measured from 24 hr to 48 hr Spodoptera exigua 66.85 %
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 8 g/l measured from 24 hr to 48 hr Spodoptera exigua 56.82 %
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 4 g/l measured from 24 hr to 48 hr Spodoptera exigua 49.63 %
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 2 g/l measured from 24 hr to 48 hr Spodoptera exigua 42.68 %
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 1 g/l measured from 24 hr to 48 hr Spodoptera exigua 37.96 %
Antinociceptive activity Swiss albino Mus musculus (mouse) assessed as inhibition of formalin-induced paw licking at 10 mg/kg, po administered 60 min prior to formalin-challenge measured from 15 to 30 min relative to control Mus musculus 48.64 %
Antinociceptive activity Swiss albino Mus musculus (mouse) assessed as inhibition of formalin-induced paw licking at 10 mg/kg, po administered 60 min prior to formalin-challenge measured up to 5 min relative to control Mus musculus 40.31 %
Antinociceptive activity in Swiss albino Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po administered 1 hr prior to acetic acid-challenge measured up to 20 min relative to control Mus musculus 55.35 %
Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of cotton pellet-induced granuloma formation at 10 mg/kg, po administered QD for 5 days measured at 1 hr post-last dose relative to control Mus musculus 36.98 %
Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 30 min prior to carrageenan-challenge measured after 5 hr relative to control Mus musculus 50.0 %
Inhibition of recombinant FLT3 (unknown origin) by TR-FRET assay Homo sapiens 830.0 nM
Antioxidant activity assessed as inhibition of lipid peroxidation activity after 15 mins by MDA assay None 149.7 ug.mL-1
Hemolysis of human erythrocytes after 30 mins by spectrophotometry Homo sapiens 107.28 ug.mL-1
Antioxidant activity assessed as DPPH scavenging activity after 30 mins by UV-visible spectrophotometry None 44.18 ug.mL-1
Antioxidant activity assessed as superoxide radical scavenging activity after 5 mins by spectrophotometry None 31.01 ug.mL-1
Inhibition of human recombinant aldose reductase Homo sapiens 600.0 nM
Inhibition of bovine lens aldose reductase using DL-glyceraldehyde as substrate assessed as NADPH oxidation measured for 10 mins by spectrophotometric analysis Bos taurus 754.0 nM
Inhibition of MPO release in zymosan-stimulated human neutrophils by luminol-dependent chemiluminescence assay Homo sapiens 100.0 %
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Homo sapiens 900.0 nM
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Human immunodeficiency virus 1 2.48 ug.mL-1
Inhibition of His6-tagged HIV-1 integrase assessed as decrease in integrase-Flag-LEDGF/p75 interaction preincubated with enzyme for 30 mins followed by addition of Flag-LEDGF/p75 for 1 hr by AlphaScreen assay Human immunodeficiency virus 1 450.0 nM
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method Mus musculus 210.0 nM
Inhibition of alpha glucosidase (unknown origin) at 0.5 mg/ml Homo sapiens 36.0 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 1 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 6.2 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 3 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 13.5 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 10 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 38.1 %
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 30 uM after 72 hrs by microplate reader analysis relative to control Mus musculus 76.7 %
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 10 uM after 5 mins by microplate reader analysis relative to control Agaricus bisporus 11.4 %
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 100 uM after 5 mins by microplate reader analysis relative to control Agaricus bisporus 33.5 %
Inhibition of plasmin (unknown origin) at 100 uM after 18 hrs by arianor mahogany dye-based fibrin plate assay relative to control Homo sapiens 28.7 %
Binding affinity to TTR (unknown origin) by isothermal titration calorimetric analysis Homo sapiens 70.0 nM
Inhibition of xanthine oxidase (unknown origin) using xanthine as substrate at 33 to 100 umol/L after 10 mins by HPLC method relative to control Homo sapiens 50.0 %
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 100 uM pre-incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition Rattus norvegicus 26.55 %
Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay Homo sapiens 4.7 nM
Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay Homo sapiens 60.3 nM
Inhibition of human recombinant carbonic anhydrase 4 Homo sapiens 293.0 nM
Inhibition of recombinant human AKR1B10 expressed in human HCT116 cells assessed as reduction in daunorubicinol production using daunorubicin as substrate at 20 uM incubated for 4 to 8 hrs by UHPLC based transient transfection assay Homo sapiens 33.0 %
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by alamar blue staining based fluorescence analysis Trypanosoma brucei rhodesiense 3.7 ug.mL-1
Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis Rattus norvegicus 9.4 ug.mL-1
Antileishmanial activity against Leishmania donovani MHOM/ET/67/L82 after 72 hrs by Alamar blue dye based fluorescence analysis Leishmania donovani 0.8 ug.mL-1
Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method Trypanosoma cruzi 21.4 ug.mL-1
Inhibition of Bcl-2 (unknown origin) using FAM-Bid peptide as substrate at 50 uM by fluorescence polarization-based assay Homo sapiens 46.0 %
Inhibition of Bcl-XL (unknown origin) using FAM-Bid peptide as substrate at 50 uM by fluorescence polarization-based assay Homo sapiens 49.0 %
Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relative to control Homo sapiens 31.12 %
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production at 5 uM by ELISA relative to control Mus musculus 19.5 %
Inhibition of recombinant human CYP1B1 expressed in supersomes using ethoxyresorufin as substrate preincubated for 5 mins followed by substrate addition in presence of NADPH by fluorimetric analysis Homo sapiens 360.0 nM
Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM incubated for 24 hrs under dark condition by thioflavin-T based fluorometric assay relative to control Homo sapiens 86.5 %
Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate at 200 uM preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins relative to control Saccharomyces cerevisiae 99.6 %
Inhibition of DPP4 (unknown origin) using Gly-Pro-AMC as substrate preincubated for 4 secs followed by substrate addition and measured after 30 mins by luminescence assay Homo sapiens 120.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 1.01 %
Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 1 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control Homo sapiens 19.8 %
Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 5 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control Homo sapiens 40.75 %
Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 10 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control Homo sapiens 39.92 %
Inhibition of human recombinant CK2 expressed in Escherichia coli using RRRADDSDDDDD as substrate after 10 mins in presence of [gamma-32P]ATP Homo sapiens 500.0 nM
Inhibition of PKC in rat brain homogenate at 50 uM using FKKSFKL-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins in presence of [gamma-32P]ATP by liquid scintillation counting analysis relative to control Rattus norvegicus 70.0 %
Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control Escherichia coli 0.0 %
Inhibition of T0901317-induced LXR-alpha/beta transactivation in mouse RAW264.7 cells assessed as reduction in ABCA1 mRNA expression at 25 uM after 3 hrs by RT-PCR method relative to control Mus musculus 41.0 %
Inhibition of T0901317-induced LXR-alpha/beta transactivation in mouse RAW264.7 cells assessed as reduction in ABCA1 mRNA expression at 50 uM after 3 hrs by RT-PCR method relative to control Mus musculus 64.0 %
Antihyperlipidemic activity in ethanol-induced steatosis C57BL/6 mouse model assessed as inhibition of serum triacylglycerol level at 50 mg/kg, po administered daily through oral gavage for 2 weeks by colorimetric method relative to control Mus musculus 22.0 %
Antihyperlipidemic activity in ethanol-induced steatosis C57BL/6 mouse model assessed as inhibition of serum LDL cholesterol level at 50 mg/kg, po administered daily through oral gavage for 2 weeks by colorimetric method relative to control Mus musculus 52.0 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 -3.027 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.07 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.07 %
In-vivo inhibition of ICR mouse beta-glucuronidase at 20 mg/kg, sc after 10 weeks relative to DMH alone Mus musculus 14.9 %
In-vivo inhibition of ICR mouse beta-glucuronidase at 60 mg/kg, sc after 10 weeks relative to DMH alone Mus musculus 21.3 %
Inhibition of human liver FBP1 at 200 uM incubated for 5 mins by fluorescence method relative to control Homo sapiens 22.0 %
Inhibition of N-terminal GST-tagged recombinant human full length MNK2 expressed in baculovirus expression system at 10 uM incubated for 1 hr by Kinase Tracer 236 based LanthaScreen Eu kinase binding assay relative to control Homo sapiens 70.0 %
Inhibition of N-terminal GST-tagged recombinant human full length MNK2 expressed in baculovirus expression system incubated for 1 hr by Kinase Tracer 236 based LanthaScreen Eu kinase binding assay relative to control Homo sapiens 579.0 nM
Inhibition of GST-tagged recombinant human full length MNK1 expressed in insect cells at 10 uM relative to control Homo sapiens 70.0 %
Inhibition of GST-tagged recombinant human full length MNK1 expressed in insect cells Homo sapiens 179.0 nM
Inhibition of MNK1/MNK2 in human MV4-11 cells assessed as reduction in eIF4E phosphorylation reduction in eIF4E phosphorylation at 10 uM after 24 to 48 hrs by Western blot analysis Homo sapiens 100.0 %
Inhibition of MNK1/MNK2 in human MOLM-13 cells assessed as reduction in eIF4E phosphorylation reduction in eIF4E phosphorylation at 10 uM after 24 to 48 hrs by Western blot analysis Homo sapiens 100.0 %
Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoic acid binding to Influenza A virus (A/California/07/2009(H1N1)) N-terminal GST-tagged polymerase acidic subunit N-terminal domain expressed in Escherichia coli BL21 (DE3) RIL cells measured after 120 mins by Alphascreen assay Influenza A virus (A/California/07/2009(H1N1)) 72.0 nM
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 10 uM measured after 24 hrs by Griess reagent based assay relative to control Mus musculus 54.6 %
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL complex formation at 10 uM incubated for 15 mins in presence of cardiolipin by Trp-59 fluorescence assay relative to control Homo sapiens 84.0 %
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control Homo sapiens 71.0 %
Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control Homo sapiens 32.0 %

Related Entries

Cross References

Resources Reference
ChEBI 15864
ChEMBL CHEMBL151
DrugBank DB15584
FDA SRS KUX1ZNC9J2
Human Metabolome Database HMDB0005800
Guide to Pharmacology 5215
KEGG C01514
PDB LU2
PubChem 5280445
SureChEMBL SCHEMBL20426
ZINC ZINC000018185774